Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

被引：0

作者：

Tran, Ben

Horvath, Lisa

Dorff, Tanya B.

Greil, Richard

Machiels, Jean-Pascal H.

Roncolato, Felicia

Autio, Karen A.

Rettig, Matthew

Fizazi, Karim

Lolkema, Martijn P.

Fermin, Anthony C.

Salvati, Mark

Kouros-Mehr, Hosein

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Chris OBrien Lifehouse, Camperdown, NSW, Australia

[3] City Hope Natl Med Ctr, Duarte, CA USA

[4] Paracelsus Med Univ Salzburg, Salzburg Canc Res Inst CCCIT, Salzburg, Austria

[5] Canc Cluster Salzburg, Salzburg, Austria

[6] Clin Univ St Luc, Brussels, Belgium

[7] Scientia Clin Res, Randwick, NSW, Australia

[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[9] Univ Calif Los Angeles, Los Angeles, CA USA

[10] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France

[11] Erasmus MC Canc Inst, Rotterdam, Netherlands

[12] Amgen Inc, Thousand Oaks, CA 91320 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS261

引用

页数：1

共 50 条

[21] Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
Mega, Anthony E.
Petrylak, Daniel Peter
Kantoff, Philip
Stephenson, Joe
Vogelzang, Nicholas J.
Dreicer, Robert
Shore, Neal D.
Stambler, Nancy
Carpenito, Jennifer
D'Ambrosio, Paul
Israel, Robert Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[22] A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
Owonikoko, T.
Boyer, M.
Johnson, M.
Govindan, R.
Rodrigues, L.
Blackhall, F.
Boosman, R.
Champiat, S.
Hummel, H.
Lai, W. V.
Udagawa, H.
Chiang, A.
Dowlati, A.
Hann, C.
Salgia, R.
Vokes, E.
Minocha, M.
Sadraei, N.
Shetty, A.
Smit, M.
Zhang, Y.
Sable, B.
Pati, A.
Roy, S.
Borghaei, H.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S126 - S126
[23] Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
Aggarwal, Rahul Raj
Rottey, Sylvie
Aparicio, Ana
Greil, Richard
Reimers, Melissa Andrea
Sandhu, Shahneen Kaur
Zhang, Yiran
Salvati, Mark
Sadraei, Nooshin Hashemi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[24] Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)
Belli, Maria Luisa
Sarnelli, Anna
Mezzenga, Emilio
Cesarini, Francesco
Caroli, Paola
Di Iorio, Valentina
Strigari, Lidia
Cremonesi, Marta
Romeo, Antonino
Nicolini, Silvia
Matteucci, Federica
Severi, Stefano
Paganelli, Giovanni
FRONTIERS IN ONCOLOGY, 2020, 10
[25] Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Falchook, Gerald Steven
McKean, Meredith
Kelly, William Kevin
Patel, Manish R.
Bupathi, Manojkumar
Liaw, Bobby Chi-Hung
Garmezy, Benjamin
Vuu, Irene
Smith, Kristen
Lolkema, Martijn
Fong, Lawrence
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[26] Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)
Petrylak, D.
Kantoff, P.
Mega, A.
Stephenson, J.
Vogelzang, N.
Fleming, M.
Blattman, S.
Stambler, N.
D'Ambrosio, P.
Israel, R. J.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : 75 - 75
[27] Heterogeneity of prostate-specific membrane antigen (PSMA) expression in classic and apoptotic circulating tumor cells (CTC) in metastatic castration-resistant prostate cancer (mCRPC)
Autio, Karen A.
Anand, Aseem
Krupa, Rachel
Louw, Jessica
Arslan, Zaina
Dittamore, Ryan
Scher, Howard I.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[28] Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
de Kouchkovsky, Ivan
Zhang, Li
Huang, Jiaoti
Trepka, Kai
Chou, Jonathan
Foye, Adam
Shui, David
Wong, Chris
Friedl, Verena
Weinstein, Alana
Hope, Thomas A.
Quigley, David A.
Stuart, Josh
Beer, Tomasz M.
Reiter, Robert Evan
Gleave, Martin E.
Evans, Christopher P.
Feng, Felix Y.
Small, Eric Jay
Aggarwal, Rahul Raj
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[29] A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
Petrylak, Daniel Peter
Smith, David C.
Appleman, Leonard Joseph
Fleming, Mark T.
Hussain, Arif
Dreicer, Robert
Sartor, A. Oliver
Shore, Neal D.
Vogelzang, Nicholas J.
Youssoufian, Hagop
DiPippo, Vincent A.
Stambler, Nancy
Huang, Kathleen
Israel, Robert Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[30] A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
Petrylak, Daniel Peter
Smith, David C.
Appleman, Leonard Joseph
Fleming, Mark T.
Hussain, Arif
Dreicer, Robert
Sartor, A. Oliver
Shore, Neal D.
Vogelzang, Nicholas J.
Youssoufian, Hagop
Olson, William C.
Stambler, Nancy
Huang, Kathleen
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)

← 1 2 3 4 5 →